FOLD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FOLD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.
Amicus Therapeutics's Net Change in Cash for the three months ended in Sep. 2024 was $24.5 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 was $-29.5 Mil.
The historical data trend for Amicus Therapeutics's Net Change in Cash can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amicus Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Net Change in Cash | Get a 7-Day Free Trial | 63.97 | 19.82 | 83.29 | -96.34 | 96.96 |
Amicus Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Net Change in Cash | Get a 7-Day Free Trial | 51.94 | -16.20 | -37.28 | -0.44 | 24.46 |
Amicus Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as
Net Change in Cash | = | Cash Flow from Operations | + | Cash Flow from Investing | + | Cash Flow from Financing | + | Effect of Exchange Rate Changes |
= | -69.091 | + | 98.064 | + | 61.677 | + | 6.312 | |
= | 97.0 |
Amicus Therapeutics's Net Change in Cash for the quarter that ended in Sep. 2024
Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.5 Mil. * For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes
= -22.971 + 34.272 + 18.19 + -5.028
= 24.5
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Amicus Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.
Bradley L Campbell | director, officer: President and CEO | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Margaret G Mcglynn | director | C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100 |
John F Crowley | director, officer: Executive Chairman | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
David Michael Clark | officer: Chief People Officer | 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Ellen Rosenberg | officer: General Counsel & Corp. Secy | C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08560 |
Samantha Prout | officer: Principal Accounting Officer | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Jeff Castelli | officer: VP, Program Management | 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Harford Simon N.r. | officer: Chief Financial Officer | AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105 |
Michael Raab | director | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
Daphne Quimi | officer: Chief Financial Officer | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Burke W Whitman | director | 13455 NOEL ROAD # 2000, DALLAS TX 75240 |
Eiry Roberts | director | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130 |
Hung Do | officer: Sr Vice President Discovery | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Michael Aaron Kelly | director | C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., NEW YORK NY 10016 |
Jay Barth | officer: Chief Medical Officer | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
From GuruFocus
By Marketwired • 09-03-2024
By GuruFocus News • 11-14-2024
By Marketwired • 10-04-2024
By GuruFocus News • 11-06-2024
By GuruFocus Research • 08-08-2024
By Marketwired • 08-30-2024
By GuruFocus Research • 03-07-2024
By Marketwired • 06-04-2024
By GuruFocus Research • 05-10-2024
By GuruFocus News • 11-15-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.